Oct 29 (Reuters) - GSK raised its 2025 sales expectations on Wednesday, helped by double-digit growth in the third-quarter in its specialty medicines, including HIV and oncology.
The drugmaker expects revenue to increase in the range of 6%-7%, compared with an earlier forecast of 3% to 5%.
US-listed shares of GSK gained 3% in overnight trading.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.